A Phase 3 interventional study of Aerosolized plus intravenous colistin and Intravenous colistin in Pneumonia, Ventilator-Associated, Colistin Adverse Reaction and Infection Due to Multidrug Resistant Acinetobacter, sponsored by Hat Yai Medical Education Center. Terminated at 1 site in Thailand. Open to participants aged 1 Day to 30 Days. Per ClinicalTrials.gov, last updated 2018-08-02.
Sponsored by Hat Yai Medical Education Center · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand — 1 open to participants now, 1 under way, none of them phase 3. Pneumonia, Ventilator-Associated · Thailand.
Among the 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand, this one is the 6th largest by enrollment, is one of 2 that started in 2016, is one of 5 in phase 3, and was the 10th registered.
420 studies on the registry are indexed under Pneumonia, Ventilator-Associated; 83 are open to participants now.
Browse Pneumonia, Ventilator-Associated studies →1 of the 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand is open now. Recruiting first, the newest first:
National University of Singapore · Sites in Thailand, India, Malaysia and 4 more countries
Ages 18+
A study can be open while its sites in Thailand have not opened yet or have stopped. Only those recruiting at a site in Thailand →
Of the 47 Pneumonia, Ventilator-Associated studies recruiting now, 36 (77%) set no upper age limit and 6 (13%) stop at 75 or younger; 6 take children under 18; 4 take healthy volunteers.
This study: 1 Day to 30 Days · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 2 started in 2016.
This study's enrollment of 204 is above the median of 115 across 276 interventional studies indexed under Pneumonia, Ventilator-Associated.
Median enrollment 106 across the 14 interventional studies. Of the 13 that completed or were terminated, 5 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 14 have an industry lead sponsor. The 10 most frequent:
Hat Yai Medical Education Center is the lead sponsor of 8 studies on the registry; 2 are open to participants now.
Hat Yai Medical Education Center has 1 study filed under Pneumonia, Ventilator-Associated — fewer than ten, so there is no comparison to draw.
1 of the studies in Pneumonia, Ventilator-Associated with a site in Thailand that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05979545National University of SingaporeEaRly impAct theraPy With Ceftazidime-avibactam Via rapID Diagnostics | 2027-10-31 |
Add it to your calendar (.ics) → With an account.
Among the 14 studies in Pneumonia, Ventilator-Associated with a site in Thailand, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is planned to compare the clinical efficacy and safety of aerosolized plus intravenous colistin vs. intravenous colistin as adjunctive therapy for the treatment of ventilator-associated pneumonia (VAP) due to pandrugs-resistant (PDR) Acinetobacter baumannii in the neonates.
This study will evaluate the neonates with VAP due to PDR-Acinetobacter baumannii who receive aerosolized plus intravenous colistin compare with intravenous colistin as adjunctive therapy. The efficacy and safety after study will be evaluated.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Neonates with VAP due to PDR-A. baumannii who receive aerosolized colistin (4 mg/kg/dose twice daily) plus intravenous colistin (3.5 mg/kg/dose twice daily)
Drug: Aerosolized plus intravenous colistin
Neonates with VAP due to PDR-A. baumannii who receive only intravenous colistin (3.5 mg/kg/dose twice daily)
Drug: Intravenous colistin
Drug page: Colistinmethanesulfonic acidStudies of Colistinmethanesulfonic acidColistinmethanesulfonic acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Aerosolized colistin at the dose of 4 mg colistin base activity (CBA)/kg twice daily (8 mg/kg/day) plus intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
Also known as: colistimethate sodium
Intravenous colistin at a dose of 3.5 mg CBA/kg/dose twice daily (7 mg/kg/day)
Also known as: colistimethate sodium
Number of Patients With Cure
Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Improved
Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Failure
Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Death
Clinical outcome is classified in 4 categories: Cure, Improved, Failure, and Death
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Eradication
Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Persistence
Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Superinfection
Microbiological response is classified in 3 categories: Eradication Persistence, Superinfection
Time frame: Through study completion, an average of 2 weeks
Number of Patients With Adverse Events That Are Related to Study Drug
Number of Patients With Adverse Events That Are Related to Study Drug, Graded According to NCI CTCAE Version 3.0 focus on neurology, pulmonology, nephrology and metabolic/laboratory.
Time frame: Through study completion, an average of 4 weeks
Plan to share: No
The record gives a start of Sep 2016, a primary completion of Oct 2017 and a completion of Oct 2017. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Colistinmethanesulfonic acid
Pneumonia, Ventilator-Associated →
Hat Yai Medical Education Center